SCHEMBL5742599

SCHEMBL5742599

CCOC(=O)NC1(CN2CCN(S(=O)(=O)c3ccc(Br)cc3)CC2=O)CCN(c2ccnc(C)c2)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.38
F2 P00734 2/20 0.38
NEK2 P51955 1/20 0.37
LSS P48449 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
LMNA P02545 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
PLAT P00750 1/20 0.34
KLKB1 P03952 1/20 0.34
MAPK1 P28482 1/20 0.34
GPR183 P32249 1/20 0.34
HTT P42858 1/20 0.34
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742755 0.91 LSS (0.44) F10F2NEK2LSSALDH1A1
SCHEMBL5741976 0.91 ATM (0.37) F10F2ATMMAPTLMNA
Hydrochloric Acid SCHEMBL5742036 0.90 ATM (0.36) F10F2ATMMAPTLMNA
SCHEMBL5742623 0.88 F10 (0.47) F10F2PLATKLKB1
Hydrochloric Acid SCHEMBL5742202 0.87 F10 (0.47) F10F2PLATKLKB1
SCHEMBL5744431 0.85 F10 (0.43) F10LSSATM
SCHEMBL5743460 0.85 F10 (0.31) F10
Hydrochloric Acid SCHEMBL5743334 0.85 F10 (0.43) F10LSSATM
Hydrochloric Acid SCHEMBL5743496 0.85 F10 (0.32) F10
SCHEMBL5740518 0.83 ATM (0.36) F10F2ATMLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US claimed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US claimed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP claimed
US-7109200-B2 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-09-19 US disclosed
EP-1340753-B1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-01-11 EP disclosed
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-26 US disclosed
EP-1340753-A1 CARBAMATE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038986-A1 Carbamate derivatives, process for producing the same and use thereof CFH, F11, F2 F10 4/4885F2 3/4885NEK2 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.